RICHMOND, Va. — Next year, Kaleo plans to release Auvi-Q 0.1 mg, a version of its epinephrine auto-injector for infants and small children. Kaleo said Monday that the Food and Drug Administration has approved its supplemental New Drug Application (sNDA) for Auvi-Q 0.1 mg, which can be used to treat life-threatening allergic reactions, including anaphylaxis,
WOONSOCKET, R.I. — CVS Health is providing a low-cost alternative Mylan’s EpiPen epinephrine auto-injector for anaphylaxis. CVS has made Impax Laboratories’ epinephrine auto-injector available at all CVS Pharmacy drug stores at a cash price of $109.99 for a two-pack. That compares with a cash price of $649.99 for the branded EpiPen and $339.99 for the
WOONSOCKET, R.I. — In the wake of the public outcry over pricing for Mylan’s EpiPen epinephrine auto-injector for anaphylaxis, CVS Health announced that it’s providing a low-cost alternative. CVS said Thursday that Impax Laboratories’ authorized generic for the Adrenaclick epinephrine auto-injector is now available at all CVS Pharmacy drug stores at a cash price of $109.99
PITTSBURGH — This week, Mylan N.V. began making an authorized generic of its EpiPen epinephrine auto-injector available to pharmacies. Mylan said its generic epinephrine auto-injector, announced in late August, carries a wholesale acquisition cost (WAC) of $300 per two-pack carton, more than 50% lower than the WAC of EpiPen 2-Pak Auto-Injectors. The generic EpiPen, which
RICHMOND, Va. — Pharmaceutical company Kaleo plans to reintroduce the Auvi-Q epinephrine auto-injector to the U.S. market in the first half of 2017. For emergency use in treating life-threatening allergic reactions such as anaphylaxis, Auvi-Q is expected to provide an option to the EpiPen from Mylan Inc., which has been lambasted by government officials, the
PITTSBURGH — In what chief executive officer Heather Bresch called “an extraordinary commercial response,” Mylan N.V. plans to release a generic version of its EpiPen epinephrine auto-injector for anaphylaxis, answering public demands to lower the cost of the potentially life-saving product. Mylan said Monday that its U.S. subsidiary expects to roll out the generic EpiPen
NEW YORK — Senate leaders have voiced concerns about a price surge for Mylan Inc.’s EpiPen, an epinephrine auto-injector for treating anaphylaxis, or potentially life-threatening allergic reactions. Sen. Chuck Grassley (R, Iowa), chairman of the Senate Judiciary Committee, and Sens. Susan Collins (R., Maine) and Claire McCaskill (D., Mo.), chairman and ranking member of the
